Understanding the mode-of-action of Cassia auriculata via in silico and in vivo studies towards validating it as a long term therapy for type II diabetes by Fauzi, Fazlin Mohd et al.
Understanding the mode-of-action of Cassia auriculata via in silico and in vivo studies 




Ethnopharmacological relevance: Cassia auriculata (CA) is used as an antidiabetic therapy in 
Ayurvedic and Siddha practice. This study aimed to understand the mode-of-action of CA via 
combined cheminformatics and in vivo biological analysis. In particular, the effect of 10 
polyphenolic constituents of CA in modulating insulin and immunoprotective pathways were 
studied.  
Materials and methods: In silico target prediction was first employed to predict the 
probability of the polyphenols interacting with key protein targets related to insulin 
signalling, based on a model trained on known bioactivity data and chemical similarity 
considerations. Next, CA was investigated in in vivo studies where induced type 2 diabetic 
rats were treated with CA for 28 days and the expression levels of genes regulating insulin 
signalling pathway, glucose transporters of hepatic (GLUT2) and muscular (GLUT4) tissue, 
insulin receptor substrate (IRS), phosphorylated insulin receptor (AKT), gluconeogenesis 
(G6PC and PCK-1), along with inflammatory mediators genes (NF-κB, IL-6, IFN-γ and 
TNF-α ) and peroxisome proliferators-activated receptor gamma (PPAR-γ) were determined 
by qPCR.  
Results: In silico analysis shows that most of the top 10 enriched targets predicted for the 
constituents of CA are involved in insulin signalling pathways e.g. PTPN1, PCK-α, AKT2, 
PI3K-γ. Some of the predictions were supported by scientific literature such as the prediction 
of MAPK4 and MAPK8 for epigallocatechin gallate. Based on the in silico and in vivo 
findings, we hypothesized that CA may enhance glucose uptake and glucose transporter 
expressions via the IRS signalling pathway. This is based on AKT2 and PI3K-γ being listed 
in the top 20 enriched targets. In vivo analysis shows significant increase in the expression of 
IRS, AKT, GLUT2 and GLUT4 CA may also affect the PPAR-γ signalling pathway. This is 
based on the CA-treated groups showing significant activation of PPAR-γ in the liver 
compared to control. PPAR-γ was predicted by the in silico target prediction with high 
normalisation rate although it was not in the top 20 most enriched targets. CA may also be 
involved in the gluconeogenesis and glycogenolysis in the liver based on the downregulation 
of G6PC and PCK-1 genes seen in CA-treated groups. In addition, CA-treated groups also 
showed decreased cholesterol, triglyceride, glucose, CRP and Hb1Ac levels, and increased 
insulin and C-peptide levels. These findings demonstrate the insulin secretagogue and 
sensitizer effect of CA.  
Conclusion: Based on both an in silico and in vivo analysis, we propose here that CA 
mediates glucose/lipid metabolism via the PI3K signalling pathway, and influence AKT 
thereby causing insulin secretion and insulin sensitivity in peripheral tissues. CA enhances 
glucose uptake and expression of glucose transporters in particular via the upregulation of 
GLUT2 and GLUT4. Thus, based on its ability to modulate immunometabolic pathways, CA 
appears as an attractive long term therapy for T2DM even at relatively low doses.  
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